{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
pantothenic acid
to a specific field?
Status:
Investigational
Source:
NCT00185042: Phase 2 Interventional Completed Coronary Heart Disease
(2002)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Daiichi Sankyo developed an inhibitor of acyl-coenzyme A:cholesterol acyltransferases (ACAT1 and ACAT2), pactimibe (also known as CS 505). Pactimibe has been used in trials phase II for reducing the progression of coronary artery disease and in patients with atherosclerosis. However, on October 26, 2005, the company made the decision to discontinue all ongoing clinical studies of pactimibe, because of the secondary endpoints that showed a lower effect of the drug on atherosclerosis than the standard of care alone and no beneficial effect on the frequency of cardiovascular events.
Class (Stereo):
CHEMICAL (RACEMIC)
Nafagrel [DP 1904, SR 96325] is a thromboxane A2 synthetase inhibitor that was undergoing clinical trials with Daiichi Seiyaku, now Daiichi Pharmaceutical, for the diabetic angiopathies, lupus nephritis and Raynaud's disease in Japan. However the development of Nafagrel has been discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
IPSALAZIDE is a sulfasalazine analog designed as a colon-specific delivery system for the treatment of inflammatory bowel disease by releasing 5-aminosalicylic acid in the gastrointestinal tract.
Status:
Investigational
Source:
INN:flubanilate [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
FLUBANILATE is a CNS stimulant.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Etiproston is a synthetic analog of prostaglandin F2α. Etiproston induces luteal regression. Etiproston is used in veterinary.
Class (Stereo):
CHEMICAL (RACEMIC)
Esafloxacin (7-(3-amino-1-pyrrolidinyl)-1-ethyl-6-fluoro-1,4 -dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acid) is an antibacterial agent.
Class (Stereo):
CHEMICAL (ACHIRAL)
Niometacin, an indometacin derivative, is a nonsteroidal anti-inflammatory drug.
Class (Stereo):
CHEMICAL (RACEMIC)
Serfibrate, a clofibrate derivative, is a peroxisome proliferator activated receptor-α (PPAR-α) agonist. It is a hypolipidemic agent.
Status:
Class (Stereo):
CHEMICAL (ACHIRAL)
Ioprocemic Acid is hydrocinnamic acid derivative patented by Schering-Kahlbaum A.-G. as radiographic contrast medium for liver imaging
Status:
Investigational
Source:
NCT00296569: Phase 2 Interventional Completed Osteoarthritis
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-0686 is a bradykinin B1 receptor antagonist patented by American multinational pharmaceutical company Merck & Co for the treatment of neuropathic pain and inflammation. MK-0686 demonstrates significantly reduced susceptibility to human P-gp mediated efflux and shows good potential for human CNS penetration based on brain levels in CF-1 mice and monkeys. Additionally, MK-0686 also exhibited good CNS bradykinin B1 receptor occupancy in the transgenic rat expressing the human B1 receptor and showed oral efficacy in reducing CFA-induced hyperalgesia in a humanized mouse. Unfortunately, in phase II clinical trials MK-0686 failed to demonstrate efficacy in phase II clinical trials.
